JP5449134B2 - 未熟児合併症の治療及び／又は予防の方法と製品 - Google Patents

未熟児合併症の治療及び／又は予防の方法と製品 Download PDF

Info

Publication number
JP5449134B2
JP5449134B2 JP2010504018A JP2010504018A JP5449134B2 JP 5449134 B2 JP5449134 B2 JP 5449134B2 JP 2010504018 A JP2010504018 A JP 2010504018A JP 2010504018 A JP2010504018 A JP 2010504018A JP 5449134 B2 JP5449134 B2 JP 5449134B2
Authority
JP
Japan
Prior art keywords
igfbp
igf
composition
birth
preterm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010504018A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010524928A5 (cg-RX-API-DMAC10.html
JP2010524928A (ja
Inventor
アン・ヘルストレム
カタリーナ・レーフクヴィスト
ロイス・スミス
Original Assignee
プレーマクレ・アクチエボラーグ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プレーマクレ・アクチエボラーグ filed Critical プレーマクレ・アクチエボラーグ
Publication of JP2010524928A publication Critical patent/JP2010524928A/ja
Publication of JP2010524928A5 publication Critical patent/JP2010524928A5/ja
Application granted granted Critical
Publication of JP5449134B2 publication Critical patent/JP5449134B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1754—Insulin-like growth factor binding proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010504018A 2007-04-18 2008-04-18 未熟児合併症の治療及び／又は予防の方法と製品 Active JP5449134B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92396307P 2007-04-18 2007-04-18
US60/923,963 2007-04-18
PCT/SE2008/050441 WO2008130315A1 (en) 2007-04-18 2008-04-18 Method and product for treatment and/or prevention of complications of prematurity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013189927A Division JP2013249317A (ja) 2007-04-18 2013-09-13 未熟児合併症の治療及び／又は予防の方法と製品

Publications (3)

Publication Number Publication Date
JP2010524928A JP2010524928A (ja) 2010-07-22
JP2010524928A5 JP2010524928A5 (cg-RX-API-DMAC10.html) 2011-05-12
JP5449134B2 true JP5449134B2 (ja) 2014-03-19

Family

ID=39875739

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010504018A Active JP5449134B2 (ja) 2007-04-18 2008-04-18 未熟児合併症の治療及び／又は予防の方法と製品
JP2013189927A Pending JP2013249317A (ja) 2007-04-18 2013-09-13 未熟児合併症の治療及び／又は予防の方法と製品

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013189927A Pending JP2013249317A (ja) 2007-04-18 2013-09-13 未熟児合併症の治療及び／又は予防の方法と製品

Country Status (5)

Country Link
US (3) US8518877B2 (cg-RX-API-DMAC10.html)
EP (1) EP2148695B1 (cg-RX-API-DMAC10.html)
JP (2) JP5449134B2 (cg-RX-API-DMAC10.html)
CN (1) CN101969983B (cg-RX-API-DMAC10.html)
WO (1) WO2008130315A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013249317A (ja) * 2007-04-18 2013-12-12 Premacure Ab 未熟児合併症の治療及び／又は予防の方法と製品

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2888899C (en) 2012-10-24 2023-02-21 Japan Innovative Therapeutics, Inc. Use of tryptase inhibitors in the treatment retinopathy of prematurity
US9510055B2 (en) 2013-01-23 2016-11-29 Sonos, Inc. System and method for a media experience social interface
US20150220498A1 (en) 2014-02-05 2015-08-06 Sonos, Inc. Remote Creation of a Playback Queue for a Future Event
US9679054B2 (en) 2014-03-05 2017-06-13 Sonos, Inc. Webpage media playback
US20150324552A1 (en) 2014-05-12 2015-11-12 Sonos, Inc. Share Restriction for Media Items
US20150356084A1 (en) 2014-06-05 2015-12-10 Sonos, Inc. Social Queue
US9874997B2 (en) 2014-08-08 2018-01-23 Sonos, Inc. Social playback queues
US9723038B2 (en) 2014-09-24 2017-08-01 Sonos, Inc. Social media connection recommendations based on playback information
US9860286B2 (en) 2014-09-24 2018-01-02 Sonos, Inc. Associating a captured image with a media item
US10645130B2 (en) 2014-09-24 2020-05-05 Sonos, Inc. Playback updates
US9690540B2 (en) 2014-09-24 2017-06-27 Sonos, Inc. Social media queue
US9959087B2 (en) 2014-09-24 2018-05-01 Sonos, Inc. Media item context from social media
EP3114852A1 (en) 2014-09-24 2017-01-11 Sonos Inc. Social media queue
EP3114625A1 (en) 2014-09-24 2017-01-11 Sonos, Inc. Social media connection recommendations based on playback information
US9667679B2 (en) 2014-09-24 2017-05-30 Sonos, Inc. Indicating an association between a social-media account and a media playback system
WO2018093797A1 (en) * 2016-11-15 2018-05-24 The Schepens Eye Research Institute, Inc. Compositions and methods for the treatment of aberrant angiogenesis
EP3681602B1 (en) * 2017-09-11 2026-04-15 Oak Hill Bio Limited Compositions for reducing the incidence of bpd
CA3082643A1 (en) 2017-11-14 2019-05-23 The Schepens Eye Research Institute, Inc. Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
JP7705106B2 (ja) * 2019-05-28 2025-07-09 ナノ－ネオ リミテッド 網膜症を治療するための組成物及び方法
WO2021216378A1 (en) 2020-04-23 2021-10-28 The Schepens Eye Research Institute, Inc. Methods and materials for treatment of fibrosis
WO2023242442A1 (en) * 2022-06-17 2023-12-21 Oak Hill Bio Limited Method of maturing/differentiating neurons and/or modulating the vagus nerve
WO2023242440A1 (en) * 2022-06-17 2023-12-21 Oak Hill Bio Limited Treament of lungs in infants
EP4598630A1 (en) * 2022-10-04 2025-08-13 Oak Hill Bio Limited Method of treating neonates with igf-1 complex
WO2024160999A1 (en) * 2023-02-03 2024-08-08 Oak Hill Bio Limited Treatment of kidney injury with igf-1 complex
JP2026504910A (ja) * 2023-02-14 2026-02-10 オーク ヒル バイオ リミテッド Ｇｉ組織における調節不全を治癒する処置

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
US5187151A (en) 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
EP0639981A4 (en) 1992-05-08 1995-06-28 Univ Jefferson ANALOGS OF THE IGF FACTOR (01/18/94).
US5563046A (en) 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
US5789547A (en) 1995-06-07 1998-08-04 Celtrix Pharmaceuticals, Inc. Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
CA2429615C (en) * 2000-11-28 2016-07-12 Children's Medical Center Corporation Determination of risk and treatment of complications of prematurity
CA2614677A1 (en) * 2005-07-15 2007-01-25 Children's Medical Center Corporation Methods for treating and diagnosing complications of premature birth
WO2008130315A1 (en) * 2007-04-18 2008-10-30 Premacure Ab Method and product for treatment and/or prevention of complications of prematurity

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013249317A (ja) * 2007-04-18 2013-12-12 Premacure Ab 未熟児合併症の治療及び／又は予防の方法と製品

Also Published As

Publication number Publication date
US20150216943A1 (en) 2015-08-06
WO2008130315A1 (en) 2008-10-30
EP2148695A4 (en) 2013-01-16
CN101969983A (zh) 2011-02-09
JP2013249317A (ja) 2013-12-12
US9463222B2 (en) 2016-10-11
EP2148695B1 (en) 2014-10-15
US20100204101A1 (en) 2010-08-12
CN101969983B (zh) 2014-11-05
US8518877B2 (en) 2013-08-27
US20130310316A1 (en) 2013-11-21
JP2010524928A (ja) 2010-07-22
EP2148695A1 (en) 2010-02-03

Similar Documents

Publication Publication Date Title
US9463222B2 (en) Methods for treatment of complications of prematurity comprising administration of IGF-I and IGFBP-3
JP5089443B2 (ja) 未熟児合併症のリスクの決定および治療
Petrie Metformin beyond type 2 diabetes: Emerging and potential new indications
Velloso Regulation of muscle mass by growth hormone and IGF‐I
Wren et al. Ghrelin enhances appetite and increases food intake in humans
Giustina et al. Insulin and GH–IGF-I axis: endocrine pacer or endocrine disruptor?
AU2002239560A1 (en) Determination of risk and treatment of complications of prematurity
IL174209A (en) Use of igf-1 for manufacture of a medicament for use in treatment of igf-1 deficiency
Kiess et al. Leptin as a metabolic regulator during fetal and neonatal life and in childhood and adolescence.
JP2023145646A (ja) 慢性肺疾患を治療するための方法および組成物
Nakao et al. Translational research of novel hormones: lessons from animal models and rare human diseases for common human diseases
GLUCKMAN Insulin-like growth factors and their binding
Skottner Biosynthesis of growth hormone and insulin-like growth factor-I and the regulation of their secretion
Engel Deciphering the role of insulin and IGF-1 in brain aging, Alzheimer’s disease, and vascular dementia
Maiteeg et al. Response to Recombinant Human Growth Hormone Therapy in Libyan Children with Growth Hormone Deficiency in Misurata
ES2355470T3 (es) Reducción del riesgo de complicaciones de la prematuridad.
Cianfarani Growth and Growth Factors
Knüpfera et al. Insulin-Like Growth Factor/Growth Hormone Axis in Intrauterine Growth and Its Role in Intrauterine Growth Retardation
Deschepper et al. Bibliography Current World Literature
van der Kaay et al. GH-IGF-IGFBP Axis and Metabolic Profile in Short Children Born Small for Gestational Age
EA044079B1 (ru) Способы и композиции, предназначенные для лечения хронических заболеваний легких
Encuentro et al. Low birth weight and endocrine dysfunction in postnatal life
Van Gool et al. Free Communications
LIM ABSENCE OF MYOSTATIN IMPROVES

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110322

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130325

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130913

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20131118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131210

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131224

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5449134

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250